Last reviewed · How we verify
ANG003 Dose B
ANG003 Dose B is an investigational RNA-targeting therapy.
ANG003 Dose B is an investigational RNA-targeting therapy. Used for Investigational treatment for COVID-19.
At a glance
| Generic name | ANG003 Dose B |
|---|---|
| Sponsor | Anagram Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
ANG003 Dose B is an investigational RNA-targeting therapy that targets a specific RNA molecule to modulate gene expression.
Approved indications
- Investigational treatment for COVID-19
Common side effects
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |